SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells

RNA Biology

Volumn 12, Issue 10, 2015, Pages 1139-1151

  Gautrey, Hannah ^a   Jackson, Claire ^a   Dittrich, Anna Lena ^a   Browell, David ^b   Lennard, Thomas ^a   Tyson Capper, Alison ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; HER2; hnRNP H1; RNA binding proteins; Splice variants; SRSF3

Indexed keywords

BETA ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H1; MESSENGER RNA; MESSENGER RNA PRECURSOR; SRSF3 PROTEIN; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN GROUP F H; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING FACTOR; SRSF3 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; EXON; GENE EXPRESSION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INTRON; PROTEIN DEGRADATION; PROTEIN RNA BINDING; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP F-H; HUMANS; RECEPTOR, ERBB-2; RNA-BINDING PROTEINS; SERINE-ARGININE SPLICING FACTORS;

EID: 84954545310     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.1080/15476286.2015.1076610     Document Type: Article

References (39)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12; http://dx. doi. org/10. 1126/science. 2470152
2. Bartsch R, Wenzel C, Steger GG. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 2007; 1: 19-31.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84; PMID: 16236738; http://dx. doi. org/ 10. 1056/NEJMoa052122
4. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26; PMID: 11821453; http://dx. doi. org/10. 1200/JCO. 20. 3. 719
5. Dittrich A, Gautrey H, Browell D, Tyson-Capper A. The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web. J Mammary Gland Biol Neoplasia 2014; 19(3-4): 253-70; PMID: 25544707
6. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-55; PMID: 9130710; http://dx. doi. org/ 10. 1093/emboj/16. 7. 1647
7. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-87; PMID: 8816440
8. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15: 2452-67; PMID: 8665853
9. Jackson C, Browell D, Gautrey H, Tyson-Capper A. Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. Int J Cell Biol 2013; 2013: 973584; PMID: 23935627; http://dx. doi. org/10. 1155/2013/973584
10. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A 1999; 96: 10869-74; PMID: 10485918; http://dx. doi. org/10. 1073/pnas. 96. 19. 10869
11. Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz C, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001; 20: 2101-11; PMID: 11360194; http://dx. doi. org/10. 1038/sj. onc. 1204305
12. Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993; 13: 2247-57; PMID: 8096058
13. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18: 2149-64; PMID: 10205169; http:// dx. doi. org/10. 1093/emboj/18. 8. 2149
14. Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998; 23: 62-8; PMID: 9808159; http://dx. doi. org/ 10. 1002/(SICI)1098-2744(199810)23: 2%3c62:: AIDMC2% 3e3. 0. CO; 2-O
15. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E, Jones FE. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009; 8: 2152-62; PMID: 19671734; http://dx. doi. org/10. 1158/1535-7163. MCT-09-0295
16. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Menard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer 2006; 13: 221-32; PMID: 16601290; http://dx. doi. org/10. 1677/ erc. 1. 01047
17. Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, et al. The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One 2011; 6: e18727; PMID: 21559085; http://dx. doi. org/10. 1371/journal. pone. 0018727
18. Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M. Mammary tumor formation and metastasis evoked by a HER2 splice variant. Cancer Res 2013; 73: 5320-7; PMID: 23867476; http://dx. doi. org/10. 1158/0008-5472. CAN-12-3186
19. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006; 25: 3234-44; PMID: 16794579; http://dx. doi. org/10. 1038/sj. emboj. 7601191
20. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009; 29: 3319-31; PMID: 19364815; http:// dx. doi. org/10. 1128/MCB. 01803-08
21. Ward TM, Iorns E, Liu X, Hoe N, Kim P, Singh S, Dean S, Jegg AM, Gallas M, Rodriguez C, et al. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene 2013; 32: 2463-74; PMID: 22751112; http:// dx. doi. org/10. 1038/onc. 2012. 256
22. Michlewski G, Caceres JF. RNase-assisted RNA chromatography. RNA (New York, NY) 2010; 16: 1673-8; http://dx. doi. org/10. 1261/rna. 2136010
23. Gautrey HL, Tyson-Capper AJ. Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One 2012; 7: e51497; PMID: 23284704; http://dx. doi. org/ 10. 1371/journal. pone. 0051497
24. Jia R, Li C, McCoy J, Deng C, Zheng Z. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 2010; 6: 806-26; PMID: 21179588; http://dx. doi. org/10. 7150/ijbs. 6. 806
25. He X, Arslan AD, PoolMD, Ho TT, Darcy KM, Coon JS, Beck WT. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 2011; 30: 356-65; PMID: 20856201; http://dx. doi. org/10. 1038/onc. 2010. 426
26. Kurokawa K, Akaike Y, Masuda K, Kuwano Y, Nishida K, Yamagishi N, Kajita K, Tanahashi T, Rokutan K. Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells. Oncogene 2014; 33: 1407-17; PMID: 23503458; http://dx. doi. org/10. 1038/onc. 2013. 86
27. Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, Stauffer JK, Zheng ZM, Harris CC. Downregulation of splicing factor SRSF3 induces p53beta, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene 2013; 32: 2792-8; PMID: 22777358; http://dx. doi. org/ 10. 1038/onc. 2012. 288
28. Jang HN, Lee M, Loh TJ, Choi SW, Oh HK, Moon H, Cho S, Hong SE, Kim do H, Sheng Z, et al. Exon 9 skipping of apoptotic caspase-2 pre-mRNA is promoted by SRSF3 through interaction with exon 8. Biochim Biophys Acta 2014; 1839: 25-32; PMID: 24321384; http://dx. doi. org/10. 1016/j. bbagrm. 2013. 11. 006
29. Honore B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues. Exp Cell Res 2004; 294: 199-209; PMID: 14980514; http://dx. doi. org/10. 1016/j. yexcr. 2003. 11. 011
30. Lefave CV, Squatrito M, Vorlova S, Rocco GL, Brennan CW, Holland EC, Pan YX, Cartegni L. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J 2011; 30: 4084-97; PMID: 21915099; http://dx. doi. org/10. 1038/emboj. 2011. 259
31. Hope NR, Murray GI. The expression profile of RNAbinding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol 2011; 42: 393-402; PMID: 21194727; http://dx. doi. org/ 10. 1016/j. humpath. 2010. 08. 006
32. Venables J, Koh C, Froehlich U, Lapointe E, Couture S, Inkel L, Bramard A, Paquet ER, Watier V, Durand M, et al. Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol Cell Biol 2008; 28: 6033-43; PMID: 18644864; http://dx. doi. org/10. 1128/MCB. 00726-08
33. Garneau D, Revil T, Fisette JF, Chabot B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem 2005; 280: 22641-50; PMID: 15837790; http://dx. doi. org/10. 1074/jbc. M501070200
34. Wang E, Aslanzadeh V, Papa F, Zhu H, de la Grange P, Cambi F. Global Profiling of Alternative Splicing Events and Gene Expression Regulated by hnRNPH/F. PLoS ONE 2012; 7: e51266.
35. Xiao X, Wang Z, Jang M, Nutiu R, Wang ET, Burge CB. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nat Struct Mol Biol 2009; 16: 1094-100; PMID: 19749754; http://dx. doi. org/ 10. 1038/nsmb. 1661
36. Millevoi S, Decorsiere A, Loulergue C, Iacovoni J, Bernat S, Antoniou M, Vagner S. A physical and functional link between splicing factors promotes premRNA 30 end processing. Nucleic Acids Res 2009; 37: 4672-83; PMID: 19506027; http://dx. doi. org/ 10. 1093/nar/gkp470
37. Millevoi S, Vagner S. Molecular mechanisms of eukaryotic pre-mRNA 30 end processing regulation. Nucleic Acids Res 2010; 38: 2757-74; PMID: 20044349; http:// dx. doi. org/10. 1093/nar/gkp1176
38. Lou H, Neugebauer KM, Gagel RF, Berget SM. Regulation of alternative polyadenylation by U1 snRNPs and SRp20. Mol Cell Biol 1998; 18: 4977-85; PMID: 9710581
39. Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, Donohue JP, Shiue L, Hoon S, Brenner S, et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep 2012; 1: 167-78; PMID: 22574288; http://dx. doi. org/ 10. 1016/j. celrep. 2012. 02. 001